Abstract: A flavonoid polyphenol drug self-emulsifying composition based on a flavonoid polyphenol drug-phospholipid complex being used as an intermediate, the composition comprising a flavonoid polyphenol drug-phospholipid complex, an oil phase, an emulsifier and a co-emulsifier, the flavonoid polyphenol drug comprising one or more selected from baicalein, proanthocyanidin, quercetin, curcumin and resveratrol. The described self-emulsifying composition has the beneficial effects of good stability, a high amount of drug loading, high bioavailability, and so on.

Abstract: The present invention belongs to the technical field of protein and genetic engineering, and specifically discloses use of an erythropoietin human hepatocyte receptor B4 as a target in screening and preparing a biological formulation or medicament for increasing sensitivity to insulin. Also disclosed is use of an erythropoietin human hepatocyte receptor B4 in preparing an insulin-sensitized mouse model. On the basis of insulin signal regulation, a protein EphB4 capable of interacting with an insulin receptor (InsR) is found. The protein can interact with InsR, and insulin stimulation can promote the interaction between the two, which provides a basis for insulin resistance in the case of hyperinsulinaemia. Over-expression of EphB4 can promote degradation of InsR. Inhibition of EphB4 can enhance the sensitivity to insulin and improve insulin resistance.

Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

Abstract: A dianthrone compound may be used in preparation of a medicament for prevention and/or treatment of myocardial ischemic diseases and related diseases thereof. The dianthrone compound includes trans-emodin dianthrone and/or cis-emodin dianthrone.

Abstract: The invention relates to the field of pharmaceutical chemistry, and it particularly relates to a left-handed bicyclic morpholine and a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition and use thereof in the preparation of medicaments for preventing and/or treating liver diseases and the like.

Abstract: The invention relates to quinazoline compounds, the preparation method, use, and the pharmaceutical composition thereof. The said quinazoline compounds, which are represented by Formula (I), are phosphatidylinositol 3-kinase (PI3K) inhibitors, and can be applied to prevent and/or treat PI3K activity-related diseases, such as cancer, immune diseases, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders or neurological diseases.

Abstract: The present invention relates to a benzamide compound and a preparation method, use and pharmaceutical composition thereof. The benzamide compound represented by formula (I) is a STAT3 inhibitor, and can be used to prevent and/or treat a disease related to STAT3 activity, such as a tumor, autoimmune disease, renal disease, cardiovascular disease, inflammation, metabolic/endocrine dysfunction, and neurological disease.

Abstract: The present invention belongs to the field of medical technology and relates to a class of functional small molecules targeting proteolysis pathways, a preparation and an application thereof. Specifically, the present invention relates to functional small molecules represented by formula (M) and pharmaceutically acceptable salts thereof, as well as the application of said compounds and pharmaceutical compositions thereof in the preparation of tumor-treating drugs. The functional small molecules are obtained by means of linking a compound containing a peroxide bridge linkage and a substrate of an E3 ubiquitin ligase complex. The related functional molecules can promiscuously target and bind to multiple proteins comprising functional proteins in the proteolysis pathway and have anti-tumor biological activity.

Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.

Abstract: The present invention relates to the technical field of medicine, in particular to a chondroitin sulfate polysaccharide, and a semi-synthetic preparation method therefor and the use thereof. A metal salt of the chondroitin sulfate polysaccharide provided by the present invention has an anti-inflammatory effect, and can be used for preparing a drug against inflammatory diseases. In particular, the metal salt of the chondroitin sulfate polysaccharide provided by the present invention has anti-inflammatory and bone-protecting effects, and can be used for preparing a drug against rheumatoid arthritis and for preparing a drug against osteoarthritis. The present invention provides a method for preparing the metal salt of the chondroitin sulfate polysaccharide, and the metal salt of the chondroitin sulfate polysaccharide with different degrees of sulfation can be obtained by semi-synthetic means in the present invention. The method is simple to operate and suitable for large-scale production.

Abstract: There is provided herein a method of treating and/or alleviating vascular inflammation or vascular endothelial function disorders comprising administering 2?,3,? 5?-triacetyl-N6(3-hydroxyphenyl)adenosine of formula (I): such as in the form of a pharmaceutical composition, to a person suffering from vascular inflammation or vascular endothelial function disorders.

Abstract: The present invention provides a Diels-Alderase and use thereof, and belongs to the field of gene engineering technology. The Diels-Alderase is MaDA, and its amino acid sequence and gene sequence are represented by SEQ ID Nos. 1 and 2, respectively. The present invention also provides MaDA-1 and MaDA-2, both of which are homologous proteins of MaDA, and their amino acid sequences are represented by SEQ ID Nos. 10 and 12, respectively. The present invention has discovered that MaDA and its homologous proteins from Morus alba can stereospecifically synthesize natural products of endo configuration, and prepare D-A type natural products and their analogs in vitro using chalcones and dehydroprenyl-containing compounds as substrates, which helps to develop and utilize the medicinal value of such natural products, and also provides a possibility to synthesize other six-membered ring-containing important chemical precursors or natural products.

Abstract: The present invention provides an application of triacetyl-3-hydroxyphenyladenosine represented by formula (I) in preventing or treating non-alcoholic fatty liver disease. The triacetyl-3-hydroxyphenyladenosine can significantly reduce the levels of serum AST, ALT and TG, significantly improve liver functions, and alleviate liver steatosis. The invention provides significant curative effects for preventing or treating non-alcoholic fatty liver and has limited toxic side effects.

Abstract: The present invention discloses a nitrogen-containing heterocyclic substituted benzoxazine oxazolidinone compound, a preparation method and use thereof in the manufacture of a medicament for treating and/or preventing infectious diseases caused by Mycobacterium tuberculosis. Specifically, the present invention relates to a compound represented by formula (I) and stereoisomer thereof, pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compounds of the present invention, use thereof, a method for preparing the compound, in which X1, X2, R1 and R2 are described in the specification.

Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: The present invention discloses a nicotinyl alcohol ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to nicotinyl alcohol ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.

Abstract: Provided is a method for preparing 2-hydroxy-4-(2, 3-disubstituted benzyloxy)-5-substituted benzaldehyde derivative represented by formula (I). The method comprises the following steps: (1) preparing 3-aryl-2-substituted toluene derivative 2 by using 3-iodo-2-substituted toluene derivative 1 and aryl boronic acid 5 or aryl boronate as starting materials; (2) preparing a benzyl halide derivative 3 by using 3-aryl-2-substituted toluene derivative 2 as starting materials; and (3) preparing 4-(2, 3-disubstituted benzyloxy)-2-hydroxy-5-substituted benzaldehyde derivative (I) by using benzyl halide derivative 3 and 2,4-dihydroxy-5-substituted benzaldehyde 6.

Abstract: The present application relates to the use of berberine as shown in formula (I) or an active metabolite thereof and a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and/or treating phenylketonuria.